About

Company Overview

Redefining the Discovery and Design of Cancer Antibodies

Adagene is a private, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.

Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class.

We have forged strategic partnerships with multiple reputable global companies. These partnerships leverage our technology in approaches at the vanguard of science, including safer precision-guided antibody-drug conjugates, transformative antibody design and advanced CAR constructs for significant unmet needs.

Founded and led by world-class leaders in antibody discovery and engineering, we have raised more than $150 million from high-profile investors. Adagene is well-positioned to address unmet needs in areas where other treatments have had little or no success.